RxDoctor Payments Data

Adam Sturtz, PA

Surgical · Milwaukee, WINPI 1033152657

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $780 of the $980 with a category attached, or 79.6%. 9 manufacturers reported payments, led by AstraZeneca at 51.7% of the total. Reporting peaked in 2023 at $408 and has fallen 92.8% since, to $29 in 2025.

$980in general payments, 2019–2025

Across 17 payments — averaging $57.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$507
  • Amgen$121
  • Boehringer Ingelheim$120
  • Boston Scientific$102
  • Shockwave Medical, Inc$29
  • Medtronic$28
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$78080%
  • Education$20020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 85th percentile of 150 surgical providers in Wisconsin.

See all surgical providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,793
Medicare patients
98
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$91,978
BrilintaTicagrelor33$15,424
JardianceEmpagliflozin16$11,116
Ranolazine ErRanolazine28$2,202
Metoprolol Succinate169$1,714
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$863
ClopidogrelClopidogrel Bisulfate107$828
Rosuvastatin Calcium55$694
Atorvastatin Calcium101$678
Bumetanide15$424
Isosorbide Mononitrate ErIsosorbide Mononitrate43$422
Spironolactone62$404
Potassium Chloride16$372
Losartan Potassium60$366
Valsartan37$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$507$15,42433 claims
Boehringer IngelheimJardiance$120$11,11616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 surgical providers in Wisconsin.

Other surgical in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →